Genmab A (GMAB) Change in Receivables (2024 - 2026)
Genmab A's (GMAB) quarterly Change in Receivables came in at $158.0 million in Q1 2026, up 27.42% YoY from $124.0 million in Q1 2025, and up 227.42% on a QoQ basis from -$124.0 million in Q3 2025.
Genmab A (GMAB) Change in Receivables (2024 - 2026) Analysis & Trends
Genmab A (GMAB) has 3 years of Change in Receivables data on file, last reported at $158.0 million in Q1 2026.
- Quarterly Change in Receivables rose 27.42% year-over-year to $158.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.0 million (up 118.0% YoY) and the FY2025 annual result came in at -$166.0 million, up 27.83% from the prior year.
- Change in Receivables grew to $158.0 million in Q1 2026, from -$124.0 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $158.0 million in Q1 2026 to a low of -$230.0 million in Q4 2024.
- A 3-year average of -$56.8 million and a median of -$100.5 million in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2025 — Change in Receivables jumped 217.95% — and 2026, when it rose 27.42%.
- Tracing GMAB's Change in Receivables over 3 years: stood at -$230.0 million in 2024, then surged by 46.09% to -$124.0 million in 2025, then soared by 227.42% to $158.0 million in 2026.
- The last three Change in Receivables figures came in at $158.0 million (Q1 2026), -$124.0 million (Q3 2025), and -$77.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | -259.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -259.00 Mn |
| Jun 30, 2026 | -259.00 Mn |
| Mar 31, 2026 | 158.00 Mn |
| Mar 31, 2026 | 158.00 Mn |
| Sep 30, 2025 | -124.00 Mn |
| Sep 30, 2025 | -124.00 Mn |
| Jun 30, 2025 | -77.00 Mn |
| Jun 30, 2025 | -77.00 Mn |
| Mar 31, 2025 | 124.00 Mn |
| Mar 31, 2025 | 124.00 Mn |
| Dec 31, 2024 | -230.00 Mn |
| Dec 31, 2024 | -230.00 Mn |
| Sep 30, 2024 | -193.00 Mn |
| Sep 30, 2024 | -193.00 Mn |
| Jun 30, 2024 | -151.00 Mn |
| Jun 30, 2024 | -151.00 Mn |
| Mar 31, 2024 | 39.00 Mn |
| Mar 31, 2024 | 39.00 Mn |